- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Truist reiterates Rapport Therapeutics stock rating on phase 3 plans | 3 | Investing.com | ||
| Mo | Rapport Therapeutics: Truist bestätigt Kaufempfehlung nach beschleunigten Phase-3-Plänen | 5 | Investing.com Deutsch | ||
| Mi | Stifel reiterates Rapport Therapeutics stock rating after results | 4 | Investing.com | ||
| Mi | Jones Trading reiterates Rapport Therapeutics stock rating on epilepsy progress | 2 | Investing.com | ||
| Mi | BTIG raises Rapport Therapeutics stock price target on trial progress | 1 | Investing.com | ||
| 10.03. | Rapport Therapeutics GAAP EPS of -$0.72 misses by $0.03 | 1 | Seeking Alpha | ||
| 10.03. | Rapport Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.03. | Rapport Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Rapport Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.03. | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 360 | GlobeNewswire (Europe) | RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP-... ► Artikel lesen | |
| 10.03. | Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential | 1 | Investing.com | ||
| 10.03. | Citizens bekräftigt Rating für Rapport Therapeutics wegen Potenzial bei Epilepsie-Wirkstoff | 1 | Investing.com Deutsch | ||
| 09.03. | BTIG reiterates Rapport Therapeutics stock rating citing selectivity | 2 | Investing.com | ||
| 09.03. | Rapport Therapeutics: China-Deal stützt Kaufempfehlung von TD Cowen | 3 | Investing.com Deutsch | ||
| 09.03. | Rapport Therapeutics stock holds Buy at TD Cowen on China deal | 1 | Investing.com | ||
| 09.03. | Rapport Therapeutics, Inc.: Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China | 248 | GlobeNewswire (Europe) | Partnership leverages Tenacia's expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights... ► Artikel lesen | |
| 08.01. | Citizens reiterates Market Outperform rating on Rapport Therapeutics stock | 3 | Investing.com | ||
| 07.01. | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline | 780 | GlobeNewswire (Europe) | U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter... ► Artikel lesen | |
| 07.01. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Goldman Sachs bekräftigt Kaufempfehlung für Rapport Therapeutics nach Studienerfolg bei Epilepsie-Medikament | 11 | Investing.com Deutsch |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 31,170 | -0,35 % | Jefferies bestätigt Kaufempfehlung für Viking Therapeutics mit Kursziel von 101 US-Dollar | ||
| BIOCRYST PHARMACEUTICALS | 8,102 | -0,37 % | BioCryst gains amid takeover speculation | ||
| MICROBOT MEDICAL | 2,350 | -1,18 % | Microbot Medical Inc.: Microbot Medical Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event | HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced today that the Company... ► Artikel lesen | |
| IMMUNITYBIO | 7,624 | +6,78 % | NCCN erweitert Leitlinien für Blasenkrebs um Medikament von ImmunityBio | ||
| ATAIBECKLEY | 3,000 | -3,23 % | AtaiBeckley Inc.: BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day | BPL-003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts... ► Artikel lesen | |
| CYTOKINETICS | 52,00 | 0,00 % | Stifel reiterates Cytokinetics stock rating ahead of trial data | ||
| VOYAGER THERAPEUTICS | 3,920 | +4,53 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| CAPRICOR | 27,600 | +2,41 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 6,620 | 0,00 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,200 | -0,47 % | Abeona Therapeutics GAAP EPS of $1.01 misses by $0.17, revenue of $5.82M beats by $0.6M | ||
| ZEVRA THERAPEUTICS | 8,450 | -1,74 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,675 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 14,700 | 0,00 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY (sebetralstat) | Presentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in clinical trials
KalVista Pharmaceuticals... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 108,00 | -1,82 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin | Patent strengthens global intellectual property protection for QTORIN rapamycin, Palvella's lead product candidate from the QTORIN platform, in development for serious, rare skin diseases and vascular... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,080 | +6,93 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen |
Das Unternehmen RAPPORT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,190 (-0,68 %) liegt der Kurs bei 27,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.